Engineered Probiotics for Inflammatory Bowel Disease Therapeutics

Engineered probiotics harness synthetic biology to deliver therapeutic molecules, sense gut pathology and restore mucosal homeostasis in inflammatory bowel disease (IBD). These living therapeutics extend the capacity of conventional probiotics by incorporating genetic circuits for targeted drug release, immune modulation and barrier repair. Using host-friendly strains such as Escherichia coli Nissle 1917 or lactic acid bacteria, researchers have programmed functions including antioxidant enzyme expression, pathogen sensing and biofilm matrix production. Such approaches address limitations of systemic therapies by ensuring localisation to inflamed sites, minimising off-target effects and enabling real-time feedback control. Animal models demonstrate that these designer microbes can reduce inflammation, reinforce epithelial integrity and reshape the microbiota, offering a versatile platform for clinical translation.

Research from Nature Portfolio

Recent studies have engineered Escherichia coli Nissle 1917 to overexpress antioxidant enzymes, including catalase and superoxide dismutase, and encapsulated these cells within biocompatible coatings to enhance survival through the gastrointestinal tract. In murine colitis models, these programmable probiotics effectively scavenged reactive oxygen species at inflammatory sites, repaired epithelial barriers and modulated the indigenous microbiota, restoring key commensal populations. Complementary work has reprogrammed the same strain to secrete curli nanofibres displaying trefoil factors that promote mucosal healing. Oral administration of this matrix-forming probiotic accelerated recovery in chemically induced colitis, reduced histopathological damage and elicited immunomodulatory effects, thus validating in situ protein matrix delivery as a strategy to target gut inflammation.

Engineered Probiotics for Inflammatory Bowel Disease Therapeutics publication trend

The graph below shows the total number of articles in engineered probiotics for inflammatory bowel disease therapeutics across all publications each year (not limited to Nature Index journals).

Technical terms

Probiotic: Live microorganisms which, when administered in adequate amounts, confer a health benefit on the host.

Live biotherapeutic product (LBP): A medicinal preparation of live organisms used to prevent, treat or cure a disease.

Reactive oxygen species (ROS): Chemically reactive molecules containing oxygen that can drive oxidative damage in inflamed tissues.

Curli nanofibres: Amyloid protein fibres produced by bacteria that form extracellular matrices for adhesion and therapeutic display.

Trefoil factors (TFFs): Small peptides involved in mucosal protection and epithelial cell restitution.

Dextran sodium sulfate (DSS)-induced colitis: A chemical method for modelling intestinal inflammation in rodents by damaging the epithelial barrier.

Two-component system: A bacterial signalling module comprising a sensor kinase and response regulator that detects environmental signals and regulates gene expression.

References

1. Recent advances in bacteria‐based platforms for inflammatory bowel diseases treatment. Exploration (2024).
2. Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery. Nature Communications (2022).
3. Engineered E. coli Nissle 1917 for the delivery of matrix-tethered therapeutic domains to the gut. Nature Communications (2019).
4. Engineering bacterial thiosulfate and tetrathionate sensors for detecting gut inflammation. Molecular Systems Biology (2017).
5. Serine protease inhibitors protect better than IL-10 and TGF-β anti-inflammatory cytokines against mouse colitis when delivered by recombinant lactococci. Microbial Cell Factories (2015).